𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

✍ Scribed by Christopher W. Ryan; Walter M. Stadler; Nicholas J. Vogelzang

Book ID
109051748
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
101 KB
Volume
95
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase 2 study of carboplatin plus doce
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 79 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi

Docetaxel and ketoconazole in advanced h
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma : A phase I and pharmacokinetic study
✍ Peter J. Van Veldhuizen; Gregory Reed; Arvind Aggarwal; Joaquina Baranda; Muhamm πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract ## BACKGROUND Docetaxel has significant single‐agent activity in patients with prostate carcinoma, and ketoconazole has activity as a second‐line hormonal agent. In vitro, ketoconazole exhibits synergy with several chemotherapeutic agents. A potential drug interaction exists, however,